Stryker (SYK) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Stryker (NYSE: SYK):

• 1/30/2026 – Stryker was given a new $437.00 price target on by analysts at Robert W. Baird.
• 1/30/2026 – Stryker had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 1/30/2026 – Stryker had its price target raised by analysts at BTIG Research from $410.00 to $412.00. They now have a “buy” rating on the stock.
• 1/30/2026 – Stryker had its price target raised by analysts at Needham & Company LLC from $448.00 to $454.00. They now have a “buy” rating on the stock.
• 1/27/2026 – Stryker had its “overweight” rating reaffirmed by analysts at Piper Sandler.
• 1/26/2026 – Stryker was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating. They now have a $387.00 price target on the stock.
• 1/9/2026 – Stryker had its price target raised by analysts at Sanford C. Bernstein from $450.00 to $465.00. They now have an “outperform” rating on the stock.
• 1/9/2026 – Stryker was given a new $399.00 price target on by analysts at The Goldman Sachs Group, Inc..
• 1/6/2026 – Stryker was upgraded by analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating. They now have a $418.00 price target on the stock.
• 1/5/2026 – Stryker was given a new $390.00 price target on by analysts at Evercore ISI.
• 12/22/2025 – Stryker had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/21/2025 – Stryker was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/19/2025 – Stryker was upgraded by analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating. They now have a $440.00 price target on the stock.
• 12/18/2025 – Stryker had its price target lowered by analysts at Truist Financial Corporation from $400.00 to $392.00. They now have a “hold” rating on the stock.
• 12/15/2025 – Stryker had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Stryker was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/11/2025 – Stryker had its price target lowered by analysts at Citigroup Inc. from $455.00 to $420.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Stryker had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Stryker had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be issued a $0.88 dividend. The ex-dividend date is Wednesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 46.25%.

Insiders Place Their Bets

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 522,118 shares of company stock worth $185,381,932 in the last ninety days. 5.90% of the stock is owned by company insiders.

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.